$3.35
0.9%
Downside
Day's Volatility :2.35%
Upside
1.47%
37.91%
Downside
52 Weeks Volatility :52.07%
Upside
22.81%
Period | Oncocyte Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 35.48% | 6.5% | 0.0% |
6 Months | 7.35% | 7.1% | 0.0% |
1 Year | -18.25% | 9.8% | 0.0% |
3 Years | -96.77% | 14.2% | -20.2% |
Market Capitalization | 42.2M |
Book Value | $1.4 |
Earnings Per Share (EPS) | -5.32 |
PEG Ratio | 0.0 |
Wall Street Target Price | 4.19 |
Profit Margin | 0.0% |
Operating Margin TTM | -3287.5% |
Return On Assets TTM | -17.75% |
Return On Equity TTM | -132.29% |
Revenue TTM | 1.4M |
Revenue Per Share TTM | 0.17 |
Quarterly Revenue Growth YOY | -40.699999999999996% |
Gross Profit TTM | 188.0K |
EBITDA | -20.3M |
Diluted Eps TTM | -5.32 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.76 |
EPS Estimate Next Year | -2.1 |
EPS Estimate Current Quarter | -0.67 |
EPS Estimate Next Quarter | -0.6 |
What analysts predicted
Upside of 25.07%
Sell
Neutral
Buy
Oncocyte Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Oncocyte Corp | 27.27% | 7.35% | -18.25% | -96.77% | -91.3% |
![]() Idexx Laboratories, Inc. | -3.67% | -10.34% | -15.37% | -31.35% | 65.77% |
![]() Agilent Technologies Inc. | 1.42% | 3.05% | 5.07% | -10.16% | 94.22% |
![]() Thermo Fisher Scientific, Inc. | 6.51% | 8.62% | 3.5% | 12.36% | 106.99% |
![]() Danaher Corp. | 6.51% | 15.92% | 1.97% | -6.92% | 89.83% |
![]() Iqvia Holdings Inc. | 10.0% | 7.5% | 0.14% | -6.07% | 45.29% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Oncocyte Corp | NA | NA | 0.0 | -2.76 | -1.32 | -0.18 | NA | 1.4 |
![]() Idexx Laboratories, Inc. | 45.67 | 45.67 | 4.75 | 11.06 | 0.72 | 0.23 | NA | 18.93 |
![]() Agilent Technologies Inc. | 31.63 | 31.63 | 2.7 | 5.2 | 0.21 | 0.08 | 0.01 | 21.31 |
![]() Thermo Fisher Scientific, Inc. | 35.72 | 35.72 | 2.81 | 21.71 | 0.14 | 0.05 | 0.0 | 120.87 |
![]() Danaher Corp. | 48.76 | 48.76 | 3.13 | 6.99 | 0.08 | 0.04 | 0.0 | 68.92 |
![]() Iqvia Holdings Inc. | 30.13 | 30.13 | 1.33 | 11.19 | 0.23 | 0.05 | NA | 36.83 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Oncocyte Corp | Buy | $42.2M | -91.3% | NA | 0.0% |
![]() Idexx Laboratories, Inc. | Buy | $38.8B | 65.77% | 45.67 | 23.26% |
![]() Agilent Technologies Inc. | Buy | $38.9B | 94.22% | 31.63 | 18.84% |
![]() Thermo Fisher Scientific, Inc. | Buy | $219.4B | 106.99% | 35.72 | 14.2% |
![]() Danaher Corp. | Buy | $191.9B | 89.83% | 48.76 | 17.83% |
![]() Iqvia Holdings Inc. | Buy | $42.3B | 45.29% | 30.13 | 9.39% |
Insights on Oncocyte Corp
Revenue is down for the last 4 quarters, 463.0K → 176.0K (in $), with an average decrease of 26.0% per quarter
Netprofit is up for the last 2 quarters, -15.99M → -9.12M (in $), with an average increase of 75.2% per quarter
In the last 1 year, Agilent Technologies Inc. has given 5.1% return, outperforming this stock by 23.3%
In the last 3 years, Oncocyte Corp has experienced a drawdown of -96.8%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 86.6%
BROADWOOD CAPITAL Inc
PURA VIDA INVESTMENTS, LLC
Vanguard Group Inc
Morgan Stanley - Brokerage Accounts
Geode Capital Management, LLC
BlackRock Inc
oncocyte is focused on the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics to facilitate clinical decision making in the early detection of cancer. the company's pipeline is focused on molecular tests for areas of high unmet need - lung, breast, and bladder cancers - where the current standard of diagnostic care is often ambiguous, costly, and involves invasive surgical procedures. oncocyte's diagnostics are developed based on a proprietary set of biomarkers that have been shown to differentiate benign from malignant nodules or masses. for more information, visit www.oncocyte.com.
Organization | Oncocyte Corp |
Employees | 43 |
CEO | Mr. Joshua Riggs |
Industry | Health Technology |
A Spac I Acquisition Corp
$3.35
-0.45%
Keyarch Acquisition Corp
$3.35
-0.45%
Connexa Sports Technologies Inc
$3.35
-0.45%
Us Value Etf
$3.35
-0.45%
First Wave Biopharma Inc
$3.35
-0.45%
Global X Msci Next Emerging
$3.35
-0.45%
Fat Projects Acquisition Corp
$3.35
-0.45%
Capital Link Global Fintech
$3.35
-0.45%
Applied Uv Inc
$3.35
-0.45%